139 related articles for article (PubMed ID: 21266894)
1. CNS drug development: part III: future directions.
Preskorn SH
J Psychiatr Pract; 2011 Jan; 17(1):49-52. PubMed ID: 21266894
[TBL] [Abstract][Full Text] [Related]
2. CNS drug development. Part I: The early period of CNS drugs.
Preskorn SH
J Psychiatr Pract; 2010 Sep; 16(5):334-9. PubMed ID: 20859110
[TBL] [Abstract][Full Text] [Related]
3. CNS drug development: Part II: Advances from the 1960s to the 1990s.
Preskorn SH
J Psychiatr Pract; 2010 Nov; 16(6):413-5. PubMed ID: 21107146
[TBL] [Abstract][Full Text] [Related]
4. CNS Drug Development: Lessons Learned Part 3: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade-Implications for the Field.
Preskorn SH
J Psychiatr Pract; 2017 Sep; 23(5):352-360. PubMed ID: 28961664
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
7. Opportunities and challenges in the discovery of new central nervous system drugs.
Krause JE; Chenard BL
Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
[TBL] [Abstract][Full Text] [Related]
8. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
Pangalos MN; Schechter LE; Hurko O
Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
10. CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approach.
Preskorn SH
J Psychiatr Pract; 2015 Jan; 21(1):60-6. PubMed ID: 25603452
[TBL] [Abstract][Full Text] [Related]
11. Receptorome screening for CNS drug discovery.
Vortherms TA; Roth BL
IDrugs; 2005 Jun; 8(6):491-6. PubMed ID: 15906196
[TBL] [Abstract][Full Text] [Related]
12. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
13. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
14. Towards a clinical methodology for neuropsychopharmacological research.
Ban TA
Neuropsychopharmacol Hung; 2007 Jun; 9(2):81-90. PubMed ID: 17970531
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of antiepileptic and antimyoclonic drugs.
Pranzatelli MR; Nadi NS
Adv Neurol; 1995; 67():329-60. PubMed ID: 8848979
[TBL] [Abstract][Full Text] [Related]
16. From genes to therapeutic targets for psychiatric disorders - what to expect?
Muglia P
Curr Opin Pharmacol; 2011 Oct; 11(5):563-71. PubMed ID: 21893430
[TBL] [Abstract][Full Text] [Related]
17. CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes-Tasimelteon as an Example.
Preskorn SH
J Psychiatr Pract; 2017 Nov; 23(6):425-430. PubMed ID: 29303950
[TBL] [Abstract][Full Text] [Related]
18. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the search for drugs to treat central nervous system disorders.
Enna SJ; Williams M
J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
[TBL] [Abstract][Full Text] [Related]
20. A role for fMRI in optimizing CNS drug development.
Borsook D; Becerra L; Hargreaves R
Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
